Diabetes is the leading cause of chronic kidney disease due to microvascular damage to the renal blood vessels.
Read More »Diabetes and Children’s Brain Development
A recent longitudinal study examines diabetes type 1 and brain cognitive differences in children.
Read More »ADA 81st Symposium: Treatment for Prediabetes and Diabetes Can Be Found at a Grocery Store, Part 1
A prescription for vegetables can significantly lower weight, blood pressure, and A1C.
Read More »ADA 81st Symposium: Treatment for Prediabetes and Diabetes Can Be Found at a Grocery Store, Part 2
Better food choices can lower the incidence of diabetes and kidney disease, and reduce the need for medications.
Read More »ADA 81st Symposium: The Effect of Nasal Glucagon in Insulin-Induced Hypoglycemia
The preparation of nasal glucagon is immediate and intended for use in an emergency hypoglycemic event, but how well can it reverse these events?
Read More »ADA 81st Symposium: A Targeted Approach of Delivering Diabetes Education Improved Health Outcomes in Vulnerable Populations
Diet and exercise coaches are the future of preventing T2D in patients with overweight or obesity.
Read More »Mental Disorders Complicate the Treatment of Patients with Diabetes
Individuals with mental health disorders have an increased risk for type 2 diabetes and premature death; modifiable risk factors affected by antipsychotics are obesity, insulin resistance, diabetes, and dyslipidemia.
Read More »ADA 81st Symposium: Comparison of Dexcom G6 Continuous Glucose Monitoring Performance between Abdomen and Upper Arm Placement
Alternative site placement of continuous glucose monitor device is assessed in the hospital setting.
Read More »ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population
Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?
Read More »ADA 2021: Lowering of Blood Pressure and Pulse Rate by Switching from DPP-4 Inhibitor to Luseogliflozin in Patients with T2D and Hypertension
Researchers investigate the changes in ambulatory blood pressure using the antidiabetic drug in patients with type 2 diabetes and hypertension.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.